NUVALENT INC CLASS A (NUVL)
Health Care · Targeted oncology / precision medicine – tyrosine kinase inhibitors · NASDAQ
Clinical-stage oncology biotech developing selective TKIs for ROS1- and ALK-positive lung cancers, with lead candidates in FDA review as of mid-2026.
What NUVALENT INC CLASS A does
Nuvalent is a clinical-stage biopharmaceutical company developing selective tyrosine kinase inhibitors (TKIs) for patients with specific oncogenic driver mutations in non-small cell lung cancer (NSCLC). The company's lead programs include zidesamtinib (NVL-520), a ROS1-selective inhibitor, and neladalkib (NVL-655), an ALK-selective inhibitor, both designed for TKI pre-treated advanced NSCLC. As of Q1 2026, Nuvalent had submitted an NDA for zidesamtinib with an FDA target action date of September 2026, and had just submitted an NDA for neladalkib; the company has not yet generated any revenue and has no approved products.
Themes: ["targeted oncology / precision cancer medicine","ROS1-positive NSCLC","ALK-positive NSCLC","HER2-selective inhibitors","TKI resistance / second-line therapy"]
Fundamentals
- Price$123.83 as of 2026-07-09 close
- Market cap$9.8B as of 2026-07-10
- 1-year return+51.9% as of 2026-07-09 close
- ROE-42.8% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.00 as of 2026-07-10
Key risks (from latest filing)
["Clinical-stage company with no approved products and no revenue; FDA approval is uncertain and the company has not demonstrated ability to successfully develop and commercialize products","Risk of delays or failure in NDA reviews: zidesamtinib has PDUFA target date of September 2026 and neladalkib NDA was just submitted; no assurance of approval by those dates or at all","Significant manufacturing, commercialization and capital requirements ahead; the company has limited operating history (commenced significant operations in 2018) and will need to transition from R&D-focused to commercial organization while requiring substantial additional funding"]
Competitors & peers
- Pfizer (PFE)
- Eli Lilly (LLY)
- Ariad Pharmaceuticals / Takeda Oncology
- Blueprint Medicines (BPMC)
- Ignyta (acquired by Genentech/Roche)
- Exelixis (EXEL)
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.